OneSource Specialty Pharma Ltd (ONESOURCE) is currently trading at 1,582.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

OneSource Specialty Pharma Limited is a pure-play specialty pharmaceutical CDMO developing and manufacturing biologics, drug-device combinations, sterile injectables, and soft-gelatin capsules for global pharmaceutical and biotechnology customers. Its end-to-end offering spans development, clinical supply, commercial manufacturing, drug substance, drug product, devices, packaging, and cold-chain logistics across five regulatory-approved facilities. Q2FY27 marked a strong acceleration, with revenue rising 37% year on year to ₹5,162 million and EBITDA increasing 53% to ₹1,633 million. EBITDA margin expanded to 31.6%, supported by operating leverage, higher volumes, new DDC capacity, 12 launches, and execution of master service agreements across the company’s business segments. The company’s second cartridge line is now commercial, while line three has completed factory acceptance testing. Management expects DDC capacity to triple by FY28, creating a substantial runway for GLP-1 and other drug-device combination launches, with the second half expected to benefit from new launches and a meaningful commercial-volume ramp-up. Biologics momentum is broadening through a new US partner, European biosimilar customer Formycon, and repeat work from a top-three global animal-health company. The record RFP funnel spans innovators, biosimilars, and animal health, while 82-plus global customers and 75-plus active RFPs indicate a diversified opportunity set rather than reliance on a single program. OneSource Specialty Pharma Limited reaffirmed an ambitious FY28 organic revenue target of $400 million and EBITDA target of $160 million, equivalent to roughly 40% steady-state EBITDA margin. The outlook depends on converting biologics opportunities, scaling DDC capacity, expanding sterile and soft-gelatin capabilities, and sustaining execution across multiple geographic markets.

Over the past 52 weeks, OneSource Specialty Pharma Ltd has traded between a low of ₹1,075.00 and a high of ₹1,924.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

OneSource Specialty Pharma Ltd has a market capitalization of approximately 17,999.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

OneSource Specialty Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -11111.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 17,999.83 Cr, OneSource Specialty Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

OneSource Specialty Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of OneSource Specialty Pharma Ltd is -11111.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

OneSource Specialty Pharma reported standalone net profit of ₹86.2 crore for Q2 FY27, compared with ₹37.1 crore in the corresponding quarter a year earlier.

Consolidated revenue was ₹449.0 crore and EBITDA was ₹123.3 crore for Q1 FY27 (quarter ended June 30, 2026).

The company said it will host an earnings call on July 25, 2026, at 10:00 AM IST to discuss unaudited Q1 FY27 results for the quarter ended June 30, 2026.

Reports linked the fall to weak Q3 FY26 results and delays in customer approvals in Canada, especially for semaglutide, which affected revenue recognition and margins.